A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

Recruiting

Phase 1

OpevesostatA Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06860243

Conditions

Hepatic Impairment

Healthy Participants

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Accepted

Interventions

Opevesostat

Prednisone

Fludrocortisone acetate

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-30. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-11-26.